Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
11.5 GBX | 0.00% | 0.00% | +9.52% |
Apr. 17 | Bivictrix granted FDA orphan drug status for rare cancer treatment | AN |
Apr. 17 | BiVictriX Wins US FDA's Orphan Drug Status for Blood Cancer Treatment | MT |
Sales 2023 * | - | Sales 2024 * | - | Capitalization | 9.49M 12.01M |
---|---|---|---|---|---|
Net income 2023 * | -11M -13.93M | Net income 2024 * | -17M -21.52M | EV / Sales 2023 * | - |
Net Debt 2023 * | 10.76M 13.62M | Net Debt 2024 * | 28.9M 36.59M | EV / Sales 2024 * | - |
P/E ratio 2023 * |
-0.65
x | P/E ratio 2024 * |
-0.45
x | Employees | 17 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 63.35% |
6 months | -4.17% | ||
Current year | +9.52% |
Managers | Title | Age | Since |
---|---|---|---|
Tiffany Thorn
FOU | Founder | 37 | 15-12-31 |
Adrian Howd
DFI | Director of Finance/CFO | 52 | 23-10-02 |
Simon Wallwork
SEC | Corporate Secretary | - | 21-06-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michael Kauffman
CHM | Chairman | 60 | 22-01-15 |
William Paris
BRD | Director/Board Member | 73 | 21-09-21 |
Susan Lowther
BRD | Director/Board Member | 65 | 21-09-21 |
Date | Price | Change | Volume |
---|---|---|---|
24-05-17 | 11.5 | 0.00% | 0 |
24-05-16 | 11.5 | 0.00% | 67 |
24-05-15 | 11.5 | 0.00% | 0 |
24-05-14 | 11.5 | 0.00% | 10,000 |
24-05-13 | 11.5 | 0.00% | 0 |
Delayed Quote London S.E., May 17, 2024 at 02:59 am EDT
More quotesEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+9.52% | 12.03M | |
+33.37% | 50.85B | |
+1.55% | 42.82B | |
+49.05% | 42.03B | |
-4.22% | 29.55B | |
+11.57% | 26.11B | |
-21.00% | 19.13B | |
+7.36% | 13.05B | |
+28.30% | 12.16B | |
+23.80% | 12.08B |
- Stock Market
- Equities
- BVX Stock